The Clinical Science Symposium, “Precision Medicine: Making Progress for Patient Benefit,” detailed 3 large-scale efforts leveraging innovative trial designs and cutting-edge technology to break critical ground in the ability to pinpoint and use viable targeted therapies for individual patients.
Because immune responses are evolving and dynamic over time, expression of a single biomarker to select patients for treatment will really not be feasible and we should not continue on the single biomarker path.
Several Education Sessions focus on the increasing importance of immunotherapies in oncology practice and on future research directions in the field. From currently approved checkpoint inhibitors to on-the-horizon ideas, these sessions offer glimpses into a promising area of cancer therapy.
The field of immuno-oncology has revolutionized cancer care over the past decade and continues to yield new, exciting results. ASCO, in collaboration with the Society for Immunotherapy of Cancer (SITC), will be holding its first symposium on immuno-oncology next year in Orlando, Florida.
Wendy Kohlmann, Marjan Champine, and Dr. Sarah Colonna present their thoughts on discussing genetic testing with patients and their families, including obtaining informed consent, explanation of mutations, and recommendations for genetic counseling.
Results from the phase III IFCT-GFPC-0701 MAPS trial found that the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma prolonged overall survival by 2.75 months.
Advances made in next generation sequencing have allowed germline mutations to be increasingly identified in tumors and normal DNA. The significance of these findings, including whether results arising from germline testing should be returned to patients, was discussed during this session.
Two randomized phase III trials, PANORAMA-1 and ASPIRE have recently demonstrated improved response rates in patients with relapsed and refractory myeloma. The regimen of carfilzomib plus lenalidomide and dexamethasone used in ASPIRE achieved progression-free survival of 26 months.
Advances in cancer medicine and technology was the topic of discussion at this Annual Meeting Education Session regarding information retrieval, social media, and the application of technology to patient-reported outcomes.